A Phase II Study of Plerixafor, Combined with G-CSF for CD34(+) Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Autologous Transplantation. The gene discussed is CSF3; the disease is plasma cell myeloma.